Fasoracetam
Cognitive · Racetam
Tier C+
Bottom line
Read Off Label grades Fasoracetam as C+ (5.7/10) based on weak evidence, variable benefit magnitude, and a low-risk safety profile.
Developed by Nippon Shinyaku; acquired by Aevi Medical then Supernus.
Typical use: 20-400 mg/day PO in trials — Research chem; formerly investigational drug.
What this is
Developed by Nippon Shinyaku; acquired by Aevi Medical then Supernus. Phase 2 in adolescents with ADHD and mGluR network mutations showed modest effect; Phase 3 program effectively halted. Popular in nootropic circles; limited tolerance.
Mechanism
mGluR (metabotropic glutamate receptor) upregulator — unique among racetams; also GABA-B agonist activity; investigated for ADHD with mGluR gene mutations
Dose & route
20-400 mg/day PO in trials
Citations
- https://pubmed.ncbi.nlm.nih.gov/30353745/
- https://www.sec.gov/Archives/edgar/data/1613780/000121390019001648/f10k2018_aevimedicalinc.htm
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6326837/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Fasoracetam work?
- Read Off Label rates the evidence for Fasoracetam as Weak and the benefit magnitude as variable, producing an overall grade of C+ (5.7/10). Developed by Nippon Shinyaku; acquired by Aevi Medical then Supernus.
- Is Fasoracetam safe?
- Fasoracetam has a low risk profile in published human data. Legal status: Research chem; formerly investigational drug. This is not medical advice — see the disclaimer.
- What is the typical dose for Fasoracetam?
- 20-400 mg/day PO in trials
- How does Fasoracetam work?
- mGluR (metabotropic glutamate receptor) upregulator — unique among racetams; also GABA-B agonist activity; investigated for ADHD with mGluR gene mutations
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.